Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (9031)	9/2/2003 9:36:27 AM
From: Biomaven	Respond to of 52153

How screwed are the big guys? Screwed. As a group they currently can't run fast enough to do much more than stay where they are in the face of patent expirations, generic challenges and managed care formularies. The generics have an impact over and above the particular drug that is challenged - they essentially kill any new "me-too" drugs in the class as well. That said, there are still some significant "pharma sized" unmet needs in chronic conditions - obesity, diabetes, AD, osteoarthritis, fibrosis, etc. But I don't see much in the next few years in these areas. So I suspect the next 3-5 years will be tough, with most of any EPS growth coming from further consolidations and rationalizations. Peter